Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 123 results

] Title Type Year

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Z

Zhang S, Fu J, Dogan B, Scherl EJ, Simpson KW. 2018. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.. J Antibiot (Tokyo). 71(11):950-961.

Zhang N, Yantiss RK, Nam H-S, Chin Y, Zhou XKathy, Scherl EJ, Bosworth BP, Subbaramaiah K, Dannenberg AJ, Benezra R. 2014. ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury.. Stem Cell Reports. 3(5):716-24.

Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, Simpson KW. 2020. Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.. Antibiotics (Basel). 9(8)

Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al.. 2021. Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.

Y

Yarur AJ, Deepak P, Casteele NVande, Battat R, Jain A, Okada L, Osterman M, Regueiro M. 2021. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.. Dig Dis Sci. 66(10):3563-3569.

Yang E, Panaccione N, Whitmire N, Dulai PS, Casteele NVande, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R et al.. 2020. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.. Aliment Pharmacol Ther. 51(11):1031-1038.

Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, Green PHR. 2005. Inflammatory bowel disease in patients with celiac disease.. Inflamm Bowel Dis. 11(6):528-32.

W

Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS. 2010. Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.

V

Volger S, Scherl E. 2021. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy.. Clin Gastroenterol Hepatol.

Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al.. 2017. IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)

Viladomiu M, Metz ML, Lima SF, Jin W-B, Chou L, Guo C-J, Diehl GE, Simpson KW, Scherl EJ, Longman RS. 2021. Adherent-invasive E. coli metabolism of propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation.. Cell Host Microbe.

Viladomiu M, Longman RS. 2021. Decoding the matrix: multiomics reveals host-microbe biomarker for inflammatory bowel disease.. J Clin Invest. 131(9)

Verma HDev, Scherl EJanice, Jacob VElizabeth, Bosworth BPaul. 2011. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.. J Dig Dis. 12(5):379-83.

S

Steinlauf AF, Present DH. 2004. Medical management of the pregnant patient with inflammatory bowel disease.. Gastroenterol Clin North Am. 33(2):361-85,xi.

Steinlauf AF, Marion JF, Sacchar D, Sandler AL, Greenstein AJ, Harris MT. 2011. Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.. Inflamm Bowel Dis. 17(3):872-3.

Steinlauf AF, Traube M, Neitlich JD, Cooney EL. 1998. Clostridium difficile colitis: a possible cause of unexplained elevation of serum alkaline phosphatase levels in patients with AIDS.. Clin Infect Dis. 26(5):1248-9.

Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ. 1999. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements.. Hepatology. 29(4):1070-3.

Stathopoulos C, Li T, Longman R, Vothknecht UC, Becker HD, Ibba M, Söll D. 2000. One polypeptide with two aminoacyl-tRNA synthetase activities.. Science. 287(5452):479-82.

Stathopoulos C, Jacquin-Becker C, Becker HD, Li T, Ambrogelly A, Longman R, Söll D. 2001. Methanococcus jannaschii prolyl-cysteinyl-tRNA synthetase possesses overlapping amino acid binding sites.. Biochemistry. 40(1):46-52.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al.. 2018. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.

Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al.. 2021. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.

Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al.. 2012. Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.

Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Casteele NVande, Hanzel J, Crowley E, Battat R et al.. 2021. Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.. J Crohns Colitis.

Scherl EJ. 2002. Irritable-inflammatory bowel disease: recognizing a new overlap syndrome and an enigma wrapped inside a puzzle.. Inflamm Bowel Dis. 8(5):373-4.

Scherl EJ, Kumar S, Warren RU. 2010. Review of the safety and efficacy of ustekinumab.. Therap Adv Gastroenterol. 3(5):321-8.